MétaCan
Menu
Back to cohort
Record W1949697499 · doi:10.1136/bmj.326.7399.1137

Percutaneous coronary intervention. II: The procedure

2003· review· en· W1949697499 on OpenAlexaff
Ever Grech

Bibliographic record

VenueBMJ · 2003
Typereview
Languageen
FieldMedicine
TopicAcute Myocardial Infarction Research
Canadian institutionsSt. Boniface HospitalHealth Sciences Centre
Fundersnot available
KeywordsMedicineRandomized controlled trialOdds ratioConfidence intervalInternal medicineExtracorporeal membrane oxygenationClinical endpointPercutaneous coronary interventionPopulationMyocardial infarction

Abstract

fetched live from OpenAlex

<h3>Abstract</h3> <h3>Background</h3> Although convalescent plasma has been widely used to treat severe coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support its efficacy are limited. <h3>Objective</h3> To evaluate the clinical efficacy and safety of convalescent plasma among adults hospitalized with severe and critical COVID-19. <h3>Design</h3> Randomized, double-blind, controlled, multicenter, phase 2 trial conducted from April 21<sup>st</sup> to November 27<sup>th</sup>, 2020. <h3>Setting</h3> Five hospitals in New York City (NY, USA) and Rio de Janeiro (Brazil). <h3>Participants</h3> Hospitalized patients aged ≥18 years with laboratory-confirmed COVID-19, infiltrates on chest imaging and oxygen saturation ≤ 94% on room air or requirement for supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. <h3>Intervention</h3> Participants were randomized 2:1 to a single transfusion of either 1 unit of convalescent or normal control plasma. <h3>Measurements</h3> The primary outcome was clinical status at 28 days, measured using an ordinal scale and analyzed using a proportional odds model in the intention-to-treat population. <h3>Results</h3> Of 223 participants enrolled, 150 were randomized to receive convalescent plasma and 73 to normal control plasma. At 28 days, no significant improvement in clinical status was observed in participants randomized to convalescent plasma (with an odds ratio (OR) of a 1-point improvement in the scale: 1.50, 95% confidence interval (CI) 0.83-2.68, p=0.180). However, 28-day mortality was significantly lower in participants randomized to convalescent plasma versus control plasma (19/150 [12.6%] versus 18/73 [24.6%], OR 0.44, 95% CI 0.22-0.91, p=0.034). The median titer of anti-SARS-CoV-2 neutralizing antibody in infused convalescent plasma units was 1:160 (IQR 1:80-1:320). In a subset of nasopharyngeal swab samples (n=40) from Brazil that underwent genomic sequencing, no evidence of neutralization-escape mutants was detected. Serious adverse events occurred in 39/147 (27%) participants who received convalescent plasma and 26/72 (36%) participants who received control plasma. <h3>Limitations</h3> Some participants did not receive high-titer convalescent plasma. <h3>Conclusion</h3> In adults hospitalized with severe COVID-19, use of convalescent plasma was not associated with significant improvement in 28 days clinical status. The significant reduction in mortality associated with convalescent plasma, however, may warrant further evaluation. <h3>Registration</h3> ClinicalTrials.gov, NCT04359810 <h3>Funding</h3> Amazon Foundation <h3>Clinical Trial Registration</h3> ClinicalTrials.gov Identifier: NCT04359810

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesInsufficient payload (model declined to judge)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.509
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.077
GPT teacher head0.420
Teacher spread0.343 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations109
Published2003
Admission routes1
Has abstractyes

Explore more

Same venueBMJSame topicAcute Myocardial Infarction ResearchFrench-language works237,207